Adrian L James1, Tetsuya Tono2, Michael S Cohen3, Arunachalam Iyer4, Lynn Cooke5, Yuka Morita6, Keiji Matsuda2, Yutaka Yamamoto7, Masafumi Sakagami8, Matthew Yung9. 1. Department of Otolaryngology Head & Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, Canada. 2. Department of Otolaryngology, University of Miyazaki, Miyazaki, Japan. 3. Department of Otolaryngology, Harvard Medical School, Division of Pediatric Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 4. Department of Otolaryngology Head & Neck Surgery, University Hospital Monklands, Airdrie. 5. Department of Otorhinolaryngology, Gartnavel General Hospital, Glasgow, Scotland. 6. Department of Otolaryngology Head & Neck Surgery, Niigata University, Niigata. 7. Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo. 8. Department of Otolaryngology, Hyogo College of Medicine, Kobe, Japan. 9. Department of Otolaryngology, The Ipswich Hospital NHS Trust, Heath Road, Ipswich, England, UK.
Abstract
OBJECTIVE: Assessment of validity of the Japanese Otological Society and the European Academy of Otology and Neurotology (EAONO-JOS) cholesteatoma staging system (EJS) through international collaboration to investigate: (a) feasibility of retrospectively staging previously acquired data, (b) strengths and weaknesses of the staging system. METHOD: Nine centers with prospective cholesteatoma databases were recruited. Cases were allocated to EJS Stage at each center using details from time of initial surgery. An independent rater also staged the cases and noted any discrepancies. At one center results from database staging were compared with staging based on contemporaneous operative records. Inter and intrarater reliabilities were calculated, and recidivism rates calculated according to Stage. RESULTS: Of 1482 cases of cholesteatoma, 320 (22%) were Stage 1, 977 (67%) Stage 2, 153 (11%) Stage 3 and 4 (0.3%) Stage 4. No database contained details of all parameters required for accurate staging. Staging discrepancies occurred in >10% cases but inter and intrarater reliability of staging were high (Kappa 0.8; 95% confidence interval between 0.7-0.9). At 5 years, 11% had residual and 8% had recurrent cholesteatoma: rates increased with Stage but generally not significantly (Kaplan-Meier Log Rank analysis). CONCLUSION: The EJS Staging system provides an internationally agreed standard for collecting data to classify cholesteatoma severity. Although data can be applied retrospectively with reasonable reliability, prospective data collection would prevent inaccuracies that arise from missing data fields. To enhance validity of the EJS system, we propose clearer definitions of some categories. Refinements to definitions of stage may improve prognostic utility of the EJS but should be made using evidence powered by large-scale collaboration.
OBJECTIVE: Assessment of validity of the Japanese Otological Society and the European Academy of Otology and Neurotology (EAONO-JOS) cholesteatoma staging system (EJS) through international collaboration to investigate: (a) feasibility of retrospectively staging previously acquired data, (b) strengths and weaknesses of the staging system. METHOD: Nine centers with prospective cholesteatoma databases were recruited. Cases were allocated to EJS Stage at each center using details from time of initial surgery. An independent rater also staged the cases and noted any discrepancies. At one center results from database staging were compared with staging based on contemporaneous operative records. Inter and intrarater reliabilities were calculated, and recidivism rates calculated according to Stage. RESULTS: Of 1482 cases of cholesteatoma, 320 (22%) were Stage 1, 977 (67%) Stage 2, 153 (11%) Stage 3 and 4 (0.3%) Stage 4. No database contained details of all parameters required for accurate staging. Staging discrepancies occurred in >10% cases but inter and intrarater reliability of staging were high (Kappa 0.8; 95% confidence interval between 0.7-0.9). At 5 years, 11% had residual and 8% had recurrent cholesteatoma: rates increased with Stage but generally not significantly (Kaplan-Meier Log Rank analysis). CONCLUSION: The EJS Staging system provides an internationally agreed standard for collecting data to classify cholesteatoma severity. Although data can be applied retrospectively with reasonable reliability, prospective data collection would prevent inaccuracies that arise from missing data fields. To enhance validity of the EJS system, we propose clearer definitions of some categories. Refinements to definitions of stage may improve prognostic utility of the EJS but should be made using evidence powered by large-scale collaboration.
Authors: Maura C Eggink; Maarten J F de Wolf; Fenna A Ebbens; Frederik G Dikkers; Erik van Spronsen Journal: Otol Neurotol Date: 2022-04-01 Impact factor: 2.311
Authors: Daniel N Frank; Jose Pedrito M Magno; Karen Joyce S Velasco; Tori C Bootpetch; Jacob Ephraim D Salud; Kevin Jer V David; Aaron L Miller; Eljohn C Yee; Heather P Dulnuan; Richard B Pyles; Jan Alexeis C Lacuata; Jeric L Arbizo; Jennifer M Kofonow; Beatrice Guce; Kevin Michael D Mendoza; Charles E Robertson; Gabriel Martin S Ilustre; Alessandra Nadine E Chiong; Shi-Long Lu; Erik A Tongol; Nicole D Sacayan; Talitha Karisse L Yarza; Charlotte M Chiong; Regie Lyn P Santos-Cortez Journal: Front Cell Infect Microbiol Date: 2022-04-19 Impact factor: 6.073
Authors: Fleur A Ten Tije; Paul Merkus; Joeri Buwalda; Henk M Blom; Sophia E Kramer; Robert Jan Pauw Journal: Eur Arch Otorhinolaryngol Date: 2020-12-18 Impact factor: 2.503